|
| 37330047 | Effects of lifestyle and associated diseases on serum CC16 suggest complex interactions among metabolism, heart and lungs. | J Adv Res | 2024 |
| 37952114 | The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study. | J Crohns Colitis | 2024 |
| 38096402 | Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease. | J Crohns Colitis | 2024 |
| 37977914 | Genome-wide association analysis reveals the associations of NPHP4, TYW1-AUTS2 and SEMA6D for Behçet's disease and HLA-B*46:01 for its intestinal involvement. | Dig Liver Dis | 2024 |
| 38069472 | Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies. | J Crohns Colitis | 2024 |
| 36596462 | Consistency as a Data Quality Measure for German Corona Consensus Items Mapped from National Pandemic Cohort Network Data Collections. | | 2023 |
| 36112155 | [Respiratory therapy at a university hospital: evaluation of a job profile]. | Medizinische Klinik - Intensivmedizin und Notfallmedizin | 2023 |
| 35975641 | Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab. | Gut and Liver | 2023 |
| 36282973 | Interobserver Reliability of the Nancy Index for Ulcerative Colitis: An Assessment of the Practicability and Ease of Use in a Single-Centre Real-World Setting. | | 2023 |
| 36323438 | Persisting chemosensory dysfunction in COVID-19 - a cross-sectional population-based survey. | Rhinology | 2023 |
| 36323226 | Early MOnitoring of REsponse (MORE) to Golimumab Therapy: Results of a Multicentre, Prospective Observational Trial. | Dig Dis | 2023 |
| 36113491 | Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial. | Am J Gastroenterol | 2023 |
| 37603837 | The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative Colitis. | | 2023 |
| 37847261 | [Mirikizumab for ulcerative colitis]. | | 2023 |
| 37749331 | Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic T<sub>H</sub>1 cell responses in Crohn's disease. | Nat Med | 2023 |
| 37586038 | Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations. | | 2023 |
| 37718932 | Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE. | Aliment Pharmacol Ther | 2023 |
| 37891427 | Amino acid auxotrophies in human gut bacteria are linked to higher microbiome diversity and long-term stability. | | 2023 |
| 38081163 | [Cerebral Small Vessel Disease: Advances in Understanding its Pathophysiology]. | | 2023 |
| 38077747 | Acceptability Criteria of Precision Medicine: Lessons From Patients' Experiences With the GUIDE-IBD Trial Regarding the Use of Mobile Health Technology. | Crohns Colitis 360 | 2023 |
| 37621457 | Genetic and geographic influence on phenotypic variation in European sarcoidosis patients. | | 2023 |
| 37218054 | The Quality and Utility of Artificial Intelligence in Patient Care. | | 2023 |
| 37155235 | Health Status, Quality of Life, Psychosocial Well-being, and Wearables Data of Patients With Active Ulcerative Colitis Receiving Filgotinib Therapy (FilgoColitis Study): Protocol for a Real-world Observational Study. | | 2023 |
| 37404824 | Case report: Induction and maintenance of steroid-free remission with vedolizumab in a case of steroid-dependent autoimmune pancreatitis. | | 2023 |
| 37402275 | Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme. | | 2023 |
| 36646062 | A Prospective Analysis of the Metyrapone Short Test Using Targeted and Untargeted Metabolomics. | | 2023 |
| 36881032 | Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis: A Randomized Clinical Trial. | | 2023 |
| 36756874 | Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial. | | 2023 |
| 36755569 | Network-based quantitative trait linkage analysis of microbiome composition in inflammatory bowel disease families. | Front Genet | 2023 |
| 36633301 | Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study. | | 2023 |
| 37322825 | Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDO -study. | | 2023 |
| 37004656 | Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial. | | 2023 |
| 36871574 | Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. | Lancet | 2023 |
| 37314752 | A gut bacterial signature in blood and liver tissue characterizes cirrhosis and hepatocellular carcinoma. | | 2023 |
| 37250650 | Sex differences in the genetics of sarcoidosis across European and African ancestry populations. | | 2023 |
| 37436357 | Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis. | J Crohns Colitis | 2023 |
| 37436151 | Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions. | | 2023 |
| 37051808 | Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study. | | 2023 |
| 36464141 | Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment. | Clin Gastroenterol Hepatol | 2023 |
| 37425897 | Increased circulating fibronectin, depletion of natural IgM and heightened EBV, HSV-1 reactivation in ME/CFS and long COVID. | medRxiv | 2023 |
| 37364592 | Relapsing Syndrome of Inappropriate Antidiuretic Hormone Production Responding to Tolvaptan Treatment in a Patient With a Micronodular Formation of the Posterior Pituitary Gland. | | 2023 |
| 37523666 | Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study. | | 2023 |
| 37494556 | Sterile Fecal Filtrate From A Healthy Donor Improves Microbial Diversity In Patients With Hepatic Encephalopathy. | J Gastrointestin Liver Dis | 2023 |
| 37162717 | Trends in the epidemiology of Clostridioides difficile infection in Germany. | Infection | 2023 |
| 36596765 | NF-κB/RelA controlled A20 limits TRAIL-induced apoptosis in pancreatic cancer. | | 2023 |
| 35287234 | Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. | Advances in Therapy | 2022 |
| 36311771 | Brief Research Report: Serum clara cell 16 kDa protein levels are increased in patients hospitalized for severe SARS-CoV-2 or sepsis infection. | Front Immunol | 2022 |
| 36245062 | Cohort profile: the Food Chain Plus (FoCus) cohort. | European Journal of Epidemiology | 2022 |
| 36038634 | Large-scale sequencing identifies multiple genes and rare variants associated with Crohn's disease susceptibility. | Nat Genet | 2022 |
| 35904671 | The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics. | Eur J Epidemiol | 2022 |